Severe psoriasis has been demonstrated to be associated with decreased endothelial function
and an increase risk of future coronary events. Although systemic therapy with
immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic
inflammation and endothelial function are unknown.
In this study we want to assess the cardiovascular risks factors, endothelial dysfunction and
inflammatory markers before and after treatment of moderate to severe psoriasis with an
FDA-approved biologic agent, adalimumab (Humira).